Protocol Ledger

NCT05084053 · Phase III · COMPLETED

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Interventional Phase III clinical trial protocol NCT05084053 sponsored by Takeda in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-19 Enrollment: 26 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05084053
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)26 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05084053
Protocol FieldVerified Registry Value
NCT IdentifierNCT05084053
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment26 participants (ACTUAL)
Registered Start Date2022-01-19
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI